BPC-157: UK Editorial Guide to the Gastric Pentadecapeptide

By Oliver Mackman, Editorial Director · Published 19 May 2026

Hero capsule

BPC-157 is a synthetic pentadecapeptide of fifteen amino acids derived from a partial sequence first identified in human gastric juice and characterised in the 1990s by the Sikiric group at the University of Zagreb. The preclinical literature, almost entirely rodent and in vitro work, reports observations across tendon, gut, vascular, bone, and central-nervous-system models. There are no completed peer-reviewed human randomised controlled trials reporting primary outcome data. In the United Kingdom, BPC-157 holds no MHRA marketing authorisation. It is not a controlled drug under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. When sold without health or therapeutic claims, it is supplied as a research chemical for laboratory and preclinical use only.

What it is

BPC-157, short for Body Protection Compound 157, is a stable synthetic peptide of fifteen residues with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The parent molecule was identified within a larger gastric protein discussed in early Zagreb papers as a body-protection compound present in human gastric juice. The 157 designation refers to the fragment’s position and the sequence order in which it was isolated.

The peptide is sometimes described in older literature as PL 14736 or as a pentadecapeptide BPC fragment. Modern research-chemical vendors and most published papers since 2010 use the BPC-157 label consistently. It is supplied as a lyophilised white powder, reconstituted in bacteriostatic water for in vitro work, and is stable at moderate pH ranges. Its small size and proline-rich architecture make it more resistant to gastric proteolysis than many peptide candidates, which is one of the reasons it has attracted preclinical interest despite the absence of human authorisation.

The discovery story matters for evidence appraisal. The Zagreb group, led by Professor Predrag Sikiric, characterised BPC-157 in the early 1990s and has published the bulk of subsequent animal work. Independent groups in Croatia, the United States, Japan, and South Korea have contributed replication and mechanistic studies, but the single-centre concentration of the early literature is a recognised limitation that UK editorial coverage flags explicitly.

What the preclinical literature shows

The published preclinical evidence on BPC-157 spans several tissue systems. The discussion that follows summarises what animal models and in vitro work have reported. It is not a recommendation, it is not a therapeutic claim, and it is not clinical guidance. UK readers should treat every observation below as preclinical literature requiring human-trial confirmation.

Tendon and ligament models

Some of the most frequently cited BPC-157 work concerns tendon healing in rat models. Studies have documented accelerated tendon-to-bone and tendon-to-tendon repair following Achilles transection or detachment in rodents (PMID 21030672; PMID 21030673). Reported observations include increased fibroblast outgrowth from injured tendon explants in culture and changes in F-actin formation and cell migration. A separate body of rodent work has examined medial collateral ligament transection (PMID 21030674), with histological scoring suggesting improved organisation in treated animals.

The mechanistic discussion in these papers points to interactions with growth-factor pathways, including vascular endothelial growth factor receptor 2 (VEGFR2) expression and the nitric-oxide system. None of this rodent evidence has been replicated in adequately powered human RCTs as of this editorial review.

Gut and gastrointestinal models

BPC-157’s gastric-juice origin meant gut-protection studies dominated the earliest Zagreb literature. Rat models of ethanol-induced gastric ulcer, cysteamine-induced duodenal ulcer, and indomethacin-induced enteropathy have all reported reduced lesion area in treated animals (PMID 21443484; PMID 21443485). Inflammatory bowel disease rodent models, including TNBS-induced colitis, form a further preclinical cluster.

Vascular reasoning is woven through the gut literature. The Zagreb papers describe what they call an “alternative pathway” hypothesis in which BPC-157 administration in animal models is associated with rapid collateral-vessel formation around damaged segments. This vascular framing is internally consistent across the group’s output but has been independently replicated less often than the gut-protection findings themselves.

Vascular and endothelial models

Beyond the gut, several papers examine BPC-157 in rodent models of vascular injury. Work on abdominal aortic anastomosis and on venous thrombosis in rats (PMID 22950504) reports angiogenic and antithrombotic observations. In vitro endothelial-cell work points to VEGFR2 internalisation and nitric-oxide synthase modulation. These are mechanistic findings in cell and animal systems, not clinical effects in humans.

Bone and joint models

Rat fracture-healing studies and segmental bone-defect models form a smaller but consistent preclinical cluster (PMID 18345012). Reported observations include differences in callus formation and histomorphometric scoring at standard healing time points. Cartilage work in osteoarthritis rat models has been reported but the dataset is thinner and the imaging endpoints are heterogeneous across papers.

Central-nervous-system and behavioural models

A more recent line of BPC-157 work involves rodent CNS models. Papers have examined nigrostriatal lesion models, traumatic brain injury models, and behavioural readouts in anxiety and depression paradigms (PMID 27138416; PMID 21030671). Dopaminergic and serotonergic system interactions are discussed mechanistically. The CNS literature is the youngest of the major BPC-157 clusters and has the highest replication uncertainty.

Inflammation and wound-model work

Skin-wound rodent studies, burn models, and corneal-abrasion models (PMID 21030670) round out the published preclinical picture. These papers generally use standard wound-area imaging, histological scoring, and inflammatory-marker panels.

Across all six clusters, the methodological pattern is similar: rodent or in vitro design, mid-sized treatment groups, observation windows of days to weeks, and a recurring set of mechanistic candidates. The pattern is consistent enough to make BPC-157 an interesting preclinical compound. It is not consistent or human-tested enough to make it a clinical intervention.

What the literature does NOT show

Honest evidence framing matters more than enthusiastic citation counts. Several substantive gaps sit underneath the BPC-157 publication record, and a UK editorial guide should name them.

First, there are no completed and reported human randomised controlled trials with primary outcome data published in peer-reviewed journals as of May 2026. A small number of early-phase human safety studies of an oral form (referred to in older literature as PL 14736) appeared more than a decade ago, but they did not translate into a registered medicine in any major regulator’s database, including the MHRA, the EMA, the FDA, or the TGA.

Second, the literature concentrates heavily in a single research group. The Zagreb laboratory under Professor Sikiric has authored or co-authored the majority of BPC-157 papers in PubMed. Single-group concentration is not disqualifying, but it is a recognised evidence-appraisal flag. Independent replication exists in pockets, particularly in tendon and gut work from groups in Asia and North America, but the volume of independent work is small relative to the home-group output.

Third, dosing regimens in rodent papers do not translate to humans. Inter-species allometric scaling for peptide drugs is non-trivial, and the absence of human pharmacokinetic, pharmacodynamic, and dose-finding data means that every “dose” mentioned in forum literature is extrapolation. We do not publish dosing tables on PeptideClear, and UK editorial policy is to flag any retailer-side guidance on human dosing as a regulatory and safety concern.

Fourth, long-term safety data in humans does not exist. The preclinical record has reported a generally clean acute toxicity profile in rodents, but reproductive, developmental, oncogenic, and chronic-dosing endpoints in humans are entirely absent. Mast-cell-related, immunological, and tumour-microenvironment concerns are sometimes raised in commentary literature and have not been adequately addressed in human work.

Fifth, the regulatory pipeline is thin. As of editorial review, there are no Phase 2 or Phase 3 BPC-157 trials registered on clinicaltrials.gov or the UK CPMS portal with active recruitment in 2026. A small number of investigator-initiated or sports-medicine pilot proposals have been discussed in conference abstracts. None have produced peer-reviewed primary-endpoint data.

Sixth, formulation and stability data for many retailer-sold products is opaque. The peptide is sensitive to reconstitution conditions, storage temperature, and freeze-thaw cycling. Without third-party assay data from each batch, the substance in a vial labelled BPC-157 may differ in purity, integrity, and counterion content from the substance studied in the underlying papers. The CoA Trust Index that we maintain at /coa-trust-index/ is our editorial response to this opacity.

Naming these gaps is not pessimism. It is the appropriate baseline for any compound that sits between preclinical promise and clinical reality. BPC-157 is a research compound. It is not a treatment.

UK regulatory status

The UK regulatory position on BPC-157 is misunderstood often enough that it warrants a careful walk-through. Several distinct legal regimes intersect, and the answer to “is BPC-157 legal” depends on what is being asked.

The Medicines and Healthcare products Regulatory Agency (MHRA) is the body that grants marketing authorisations for medicines in the United Kingdom. BPC-157 has no MHRA marketing authorisation. It is not a licensed medicine. Any party marketing BPC-157 in the UK with health, therapeutic, or medicinal claims would be acting under the Human Medicines Regulations 2012 and would be exposed to MHRA enforcement and ASA action. This is why responsible UK research-chemical retailers do not publish dosing guidance, do not make tendon, gut, or recovery claims, and require buyers to confirm research-use intent.

The Misuse of Drugs Act 1971 schedules controlled drugs. BPC-157 is not scheduled under the 1971 Act. It is not a controlled drug under any of the classes set out in that legislation.

The Psychoactive Substances Act 2016 captures substances intended to produce a psychoactive effect. BPC-157 is not marketed for psychoactive effect and is not within the typical pharmacological frame the 2016 Act addresses.

The Advertising Standards Authority (ASA) regulates marketing communications. Any advertising of BPC-157 to UK consumers that implies medicinal benefit risks ASA upheld complaints. The CAP Code’s medicines, medical devices, health-related products, and beauty products rules apply, as do the more general rules on substantiation and harm.

Customs and import position is the area where buyers most often misread the situation. A research-use-only product, properly labelled and accompanied by appropriate documentation, sourced from a UK domestic supplier, is the lowest-friction path. Personal importation of bulk peptide material from non-UK suppliers raises distinct customs and labelling questions that fall outside the scope of this editorial. We do not recommend grey-market import.

The summary position for UK readers is this. BPC-157 is legal to possess and to sell in the UK as a research chemical when it is supplied without therapeutic or medicinal claims. It is not legal to advertise or supply BPC-157 in the UK as a medicine, as a treatment, or with explicit dosing instructions for human use. PeptideClear’s editorial framing reflects this distinction throughout.

Where UK researchers source BPC-157

PeptideClear maintains a CoA Trust Index at /coa-trust-index/ that rates UK research-peptide retailers on third-party Certificate of Analysis transparency, batch-level test publication, age and ID verification rigour, and reported complaint patterns. We rank retailers in green, amber, and red tiers. Editorial coverage on PeptideClear flags affiliate relationships explicitly. Our how-we-are-funded page sets out the model in full.

The retailers below are the UK suppliers most often relevant to research buyers seeking BPC-157.

Pure Peptides UK sits in the green tier. The retailer publishes lot-specific CoAs from independent UK laboratories, operates age verification at checkout, and has a consistent reconstitution-guidance disclaimer reminding buyers of research-use status. Editorial coverage rates Pure Peptides UK highly for documentation quality. They list BPC-157 as a standard catalogue item with batch traceability.

XL Peptides is also green tier. Their model leans on transparent third-party testing and clearly labelled batches. Customer-service responsiveness in the PeptideClear editorial sample has been good. They stock BPC-157 in standard research vial sizes and route all queries to a research-use FAQ.

Imperial Peptides holds green tier status on documentation grounds. The retailer publishes CoAs with peptide identity, purity by HPLC, and counterion content data. The editorial review noted appropriate disclaimers and no observed marketing of therapeutic benefit.

My Peptides sits in the red tier. Editorial concerns include intermittent CoA publication, unclear batch-to-batch traceability, and customer-experience reports flagged on the CoA Trust Index. We do not recommend them as a primary BPC-157 source for UK researchers until documentation improves.

UK Peptides is also red tier. The trading entity should not be confused with similarly named retailers. CoA gaps and complaint volume in the editorial sample drive the red rating. We flag this retailer specifically because its name is search-friendly and confusion with green-tier suppliers is plausible.

Retailer tiers are reviewed quarterly. The current state reflects publication and complaint data observed up to the May 2026 editorial cycle.

Common stacks involving BPC-157

In research-forum and preclinical-discussion contexts, BPC-157 is often discussed alongside other peptides. We cover the most-discussed combinations on PeptideClear’s /stacks/ hub. We do not publish human-use dosing for any stack. We summarise what the literature reports, what the rationale is, and what gaps sit in the evidence.

The combination most associated with BPC-157 in colloquial research literature is the so-called Wolverine Stack, BPC-157 paired with TB-500, the synthetic fragment of Thymosin Beta-4. The pairing is named for the comic-book character associated with rapid tissue repair. The rationale advanced in forum literature is that the two peptides operate on partially complementary mechanisms in animal tendon and soft-tissue models, with BPC-157 implicated in vascular and growth-factor pathways and TB-500 fragments implicated in actin-binding and cell-migration pathways. The combination has been discussed in rodent work and in conference abstracts, but it has not been the subject of a completed human randomised controlled trial. Our dedicated editorial entry sits at /stacks/wolverine/.

Other BPC-157 combinations occasionally referenced in research-forum and preclinical-mechanistic discussion include pairings with growth-hormone secretagogue peptides and with regenerative-focus peptides such as TA1. We treat all such combinations as preclinical-mechanistic discussion only. We do not publish stacks as protocols.

The editorial position on stacks is straightforward. Naming a stack does not validate it. The Wolverine Stack is a research-forum label. It is not a treatment regimen. UK editorial coverage frames it as background context for researchers reading the literature, not as guidance for human use.

Frequently asked questions

The FAQ block below covers six high-intent UK Google queries on BPC-157. These questions are also surfaced in structured data for AI-search visibility.

• Is BPC-157 legal in the UK? BPC-157 is not a controlled substance under the Misuse of Drugs Act 1971 and is not scheduled under the Psychoactive Substances Act 2016. It holds no MHRA marketing authorisation as a medicine. When sold without health or therapeutic claims, it is marketed in the UK as a research chemical for in vitro and preclinical use. Marketing it for human use, dosing, or therapeutic benefit would breach ASA and Human Medicines Regulations 2012 rules.

• What does BPC-157 stand for? BPC-157 stands for Body Protection Compound 157. The 157 refers to its position within the parent sequence and the order in which the fragment was characterised by the Sikiric research group at the University of Zagreb during the 1990s. It is a synthetic pentadecapeptide of fifteen amino acids derived from a sequence identified in human gastric juice.

• Has BPC-157 been tested in human clinical trials? As of editorial review in May 2026, there are no published peer-reviewed randomised controlled trials of BPC-157 in humans registered on PubMed or the WHO ICTRP that have completed and reported primary outcome data. The evidence base sits almost entirely in rodent models. UK researchers and clinicians should treat any product-level human claims with strong scepticism.

• Why is most BPC-157 research from one group? The majority of published BPC-157 literature originates from Predrag Sikiric and collaborators at the University of Zagreb, who first characterised the peptide. Single-group concentration is a recognised limitation in evidence appraisal. Independent replication outside Zagreb exists but is thinner. This is one reason UK editorial coverage frames BPC-157 evidence as preliminary rather than established.

• Where do UK researchers buy BPC-157? UK research buyers typically source BPC-157 from domestic research-chemical retailers that publish Certificates of Analysis. PeptideClear ranks UK retailers in the CoA Trust Index based on third-party testing transparency, ID checks, and complaint patterns. Currently Pure Peptides UK, XL Peptides, and Imperial Peptides hold a green tier. My Peptides and UK Peptides sit in the red tier on CoA verification concerns.

• What is the Wolverine Stack? The Wolverine Stack is the colloquial name used in research forums for the combination of BPC-157 and TB-500 (Thymosin Beta-4 fragment). It is named after the comic-book character associated with rapid tissue repair. The combination is widely discussed in animal-model and forum literature but has no UK medical authorisation and no completed human RCTs supporting the pairing.

Outstanding research questions

A constructive way to close a BPC-157 editorial is to name the open questions that would actually move the evidence base. Several are tractable and would benefit any sober UK research and clinical conversation.

The most important open question is human pharmacokinetics. There is no widely available, well-replicated human PK study describing absorption, distribution, half-life, and clearance of BPC-157 in any standard route. Without this, every rodent-derived dosing inference is speculation. A Phase 1 PK study in healthy adults, properly registered and reported, would be the single most useful contribution to the BPC-157 evidence base.

The second priority is a properly powered Achilles or patellar tendinopathy RCT. The animal evidence on tendon healing is the most coherent BPC-157 cluster, and tendinopathy is a common, costly, slow-healing condition in UK sports medicine and NHS musculoskeletal services. A well-designed Phase 2 RCT, with imaging endpoints and validated function scores, would either confirm or refute the most-cited preclinical signal.

The third priority is inflammatory-bowel-disease translation. Several decades of rodent gut-protection work, including TNBS-colitis and cysteamine-duodenal-ulcer models, point in a coherent direction. An IBD Phase 2 readout would be a clean test of whether the gut signal generalises.

The fourth priority is independent multi-centre replication of the existing preclinical work. Pre-registered animal studies, conducted outside the Zagreb group, with shared protocols and blinded endpoint adjudication, would resolve a substantial portion of the single-group concentration concern.

The fifth priority is long-term safety. Reproductive, developmental, immunological, and tumour-microenvironment endpoints have not been adequately addressed even in animal work, let alone in humans. Any serious human therapeutic conversation requires this safety scaffolding.

The sixth priority is formulation standardisation. A reference standard for BPC-157, with declared purity, counterion content, and stability profile, available to academic and commercial laboratories, would reduce the assay variance that currently sits underneath every retailer-sold vial.

Until these questions move, PeptideClear’s editorial position will remain consistent. BPC-157 is an interesting preclinical compound with a coherent rodent literature and meaningful evidence gaps. It is not a UK-authorised medicine. It is not a treatment. It is supplied in the UK as a research chemical for laboratory use, and our coverage frames it accordingly.

For our wider editorial methodology, see /methodology/. For the CoA Trust Index referenced throughout, see /coa-trust-index/. For the BPC-157 plus TB-500 entry, see /stacks/wolverine/.

This editorial reflects published literature reviewed to 19 May 2026 and is subject to revision as new data appears.